1. The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
   Fabienne McClanahan et al, 2019, Handbook of Immunosenescence CrossRef
2. CD3+CD56+ and CD3−CD56+ lymphocytes in the cerebrospinal fluid of persons with HIV-1 subtypes B and C
   Sergio M. de Almeida et al, 2023, Journal of Neuroimmunology CrossRef
3. CD4+CD56+ natural killer T‐like cells secreting interferon‐γ are associated with incident coronary events
   H. Björkbacka et al, 2016, Journal of Internal Medicine CrossRef
4. Human CD3+CD56+NKT-like cells express a range of complement receptors and C3 activation has negative effects on these cell activity and effector function
   Xiao-Yun Min et al, 2021, Human Immunology CrossRef
5. Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
   Yanyan Liu et al, 2022, Frontiers in Immunology CrossRef
6. Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia
   John C. Riches et al, 2013, Hematology/Oncology Clinics of North America CrossRef
7. Comparison of 6B11 mAb and α-GalCer-loaded CD1d dextramers for detection of iNKT cells by flow cytometry
   Marzena Lenart et al, 2017, Journal of Immunological Methods CrossRef
8. Surface profiles for subclassification of chronic lymphocytic leukemia
   Pauline Y. Huang et al, 2012, Leukemia & Lymphoma CrossRef
9. PD-1 blockade improves the anti-tumor potency of exhausted CD3 + CD56 + NKT-like cells in patients with primary hepatocellular carcinoma
   Longxiang Tao et al, 2021, OncoImmunology CrossRef
10. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer
    Suliman Y. Al Omar et al, 2012, International Immunology CrossRef
11. A matter of debate in chronic lymphocytic leukemia
    Paolo Strati et al, 2011, Current Opinion in Oncology CrossRef
12. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia
    Farhad Jadidi-Niaragh et al, 2012, Medical Oncology CrossRef
13. Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells
    Tiffany M. Zúñiga et al, 2022, Frontiers in Immunology CrossRef
14. Intracellular IL‑4 and IFN‑γ expression in iNKT cells from patients with chronic lymphocytic leukemia
    Agnieszka Bojarska‑Junak et al, 2017, Oncology Letters CrossRef
15. Diminished Frequency of Menstrual and Peripheral Blood NKT-Like Cells in Patients With Unexplained Recurrent Spontaneous Abortion and Infertile Women
    Samira Hosseini et al, 2019, Reproductive Sciences CrossRef
16. Tim‐3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer‐like T cells in patients with chronic hepatitis B
    Y.‐H. Rong et al, 2014, Tissue Antigens CrossRef
17. Phenotypic and functional exhaustion of circulating CD3+CD56+NKT‐like cells in colorectal cancer patients
    Kangli Cao et al, 2024, The FASEB Journal CrossRef
18. The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
    Fabienne McClanahan et al, 2019, Handbook of Immunosenescence CrossRef
19. Preliminary analysis of double‐negative T, double‐positive T, and natural killer T‐like cells in B‐cell chronic lymphocytic leukemia
    Luciana Valvano et al, 2023, Cancer Medicine CrossRef
20. High circulating CD3+CD56+CD16+ natural killer-like T cell levels predict a better IVF treatment outcome
    Jianjun Zhou et al, 2013, Journal of Reproductive Immunology CrossRef
21. The role of natural killer T cells in B cell malignancies
    Ghasem Ghalamfarsa et al, 2013, Tumor Biology CrossRef
22. Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD3+CD56+ NKT-Like Cells
    Siyu Zhu et al, 2022, Journal of Oncology CrossRef
23. CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma
    Carolina Cubillos-Zapata et al, 2016, OncoImmunology CrossRef
24. Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5+ B cell expansion
    Victoria L. Palmer et al, 2015, BMC Immunology CrossRef
25. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors
    Jani-Sofia Almeida et al, 2019, Frontiers in Immunology CrossRef
26. Can we define CD3+CD56+ cells as NKT cells with impunity?
    Marzena Lenart et al, 2021, Clinical Immunology CrossRef
27. A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
    Pavel Vodárek et al, 2023, Cancer Medicine CrossRef